Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial - Concepedia

Concepedia

Publication | Open Access

Dose–response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial

DOI Full Paper Access

95

Citations

21

References

2023

Year

Matthias Blüher, Julio Rosenstock, Josef Hoefler, Raymond C. Manuel, Anita M. Hennige

Abstract

Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.

References

	Year	Citations

Page 1